MARATTO

article · Journal of Medical and Life Science

Serum TNF-α levels as a biomarker in some liver diseases of Egyptian patients

20233 citationsOpen accessUniversity of Sadat City

Abstract

Background: Tumor necrosis factor alpha (TNF-α) is physiologically essential for a healthy immune response. Although TNF-α can help the immune system regulate, producing too much or inappropriate of it can be dangerous and can cause diseases. Patients and methods: this study was conducted on 90 patients with liver diseases and 25 healthy control G1, patients divided into 4 groups, (G2) 25 patients with HCV infection, (G3) 25 HCC+HCV infection, (G4) 25 patients with HBV infection, (G5) 15 patients with HCC + HBV. Results: There was a statistically significant difference between the five groups with p-value >0.001*, Compared to the control group the four groups HCV (G2), HCV+HCC (G3), HBV (G4), and HBV+HCC (G5) have the same statistically significant difference with the same (P1) p-value >0.001* which was significant. The serum TNF-α expression level of the HCV group (G2) was significantly elevated than HCV+HCC (G3) with a (P2) p-value of 0.010*significant. Still, the Serum TNF-α expression level of the HBV group (G4) was higher than HBV+HCC (G5) (61.05 ± 199.1, 14.36 ± 2.18 respectively) with (P7) p-value 0.960.Conclusion: Serum TNF-α can used as a biomarker to differentiate between healthy and infected patients with HCV or HBV and the development of HCC.

Research topics

  • Liver Disease Diagnosis and Treatment

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/jmals.2023.329303

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.